These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 14735555

  • 1. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, Freund M, Epoetin Alfa Study Group.
    Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
    [Abstract] [Full Text] [Related]

  • 2. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 3. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [Abstract] [Full Text] [Related]

  • 4. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
    Granetto C, Ricci S, Martoni A, Pezzella G, Testore F, Mattioli R, Lampignano M, Tacconi F, Porrozzi S, Gasparini G, Mantovani G, EPO-ITA3 Study Group.
    Oncol Rep; 2003 Feb; 10(5):1289-96. PubMed ID: 12883695
    [Abstract] [Full Text] [Related]

  • 7. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF.
    J Clin Oncol; 2005 Apr 20; 23(12):2606-17. PubMed ID: 15452187
    [Abstract] [Full Text] [Related]

  • 11. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.
    Glaspy J.
    Semin Hematol; 1997 Jul 20; 34(3 Suppl 2):20-6. PubMed ID: 9253780
    [Abstract] [Full Text] [Related]

  • 12. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
    Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group.
    J Clin Oncol; 2001 Jun 01; 19(11):2865-74. PubMed ID: 11387359
    [Abstract] [Full Text] [Related]

  • 13. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E.
    J Clin Oncol; 2005 Sep 01; 23(25):5960-72. PubMed ID: 16087945
    [Abstract] [Full Text] [Related]

  • 14. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study.
    Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH.
    Laryngoscope; 2002 Jul 01; 112(7 Pt 1):1221-9. PubMed ID: 12169903
    [Abstract] [Full Text] [Related]

  • 15. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J, Couture F, Young S, McWatters KL, Lau CY.
    J Clin Oncol; 2005 Apr 20; 23(12):2597-605. PubMed ID: 15452188
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.
    Mystakidou K, Kalaidopoulou O, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiatas ML, Vlahos L.
    Anticancer Res; 2005 Apr 20; 25(5):3495-500. PubMed ID: 16101168
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.
    Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, DeLeo M, Fink K, Sullivan DJ.
    J Clin Oncol; 2005 Dec 20; 23(36):9377-86. PubMed ID: 16361638
    [Abstract] [Full Text] [Related]

  • 18. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
    Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.
    Curr Med Res Opin; 2006 Oct 20; 22(10):1929-37. PubMed ID: 17022852
    [Abstract] [Full Text] [Related]

  • 19. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa.
    Agnihotri P, Telfer M, Butt Z, Jella A, Cella D, Kozma CM, Ahuja M, Riaz S, Akamah J.
    J Am Geriatr Soc; 2007 Oct 20; 55(10):1557-65. PubMed ID: 17697104
    [Abstract] [Full Text] [Related]

  • 20. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 Oct 20; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.